CUI1 stringlengths 8 8 | RELA stringlengths 3 54 | CUI2 stringlengths 8 8 | Name1 stringlengths 1 2.86k ⌀ | Name2 stringlengths 1 2.86k ⌀ | Def1 stringlengths 1 8.95k ⌀ | Def2 stringlengths 1 8.95k ⌀ |
|---|---|---|---|---|---|---|
C0000340 | disposition_of | C4521991 | Calcidiol 1-Monooxygenase | Oxidoreductase (disposition) | A mitochondrial cytochrome P450 enzyme that catalyzes the 1-alpha-hydroxylation of 25-hydroxyvitamin D3 (also known as 25-hydroxycholecalciferol) in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP27B1 gene, converts 25-hydroxyvitamin D3 to 1-alpha,25-dihydroxyvitamin D3 which is the active form of VITAMIN D in regulating bone growth and calcium metabolism. This enzyme is also active on plant 25-hydroxyvitamin D2 (ergocalciferol). | null |
C0000340 | exhibited_by | C1149070 | Calcidiol 1-Monooxygenase | 25-hydroxy vitamin D3 1-alpha-hydroxylase activity | A mitochondrial cytochrome P450 enzyme that catalyzes the 1-alpha-hydroxylation of 25-hydroxyvitamin D3 (also known as 25-hydroxycholecalciferol) in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP27B1 gene, converts 25-hydroxyvitamin D3 to 1-alpha,25-dihydroxyvitamin D3 which is the active form of VITAMIN D in regulating bone growth and calcium metabolism. This enzyme is also active on plant 25-hydroxyvitamin D2 (ergocalciferol). | Catalysis of the reaction: calcidiol + H+ + NADPH + O2 = calcitriol + H2O + NADP+. [EC:1.14.15.18, RHEA:20573] |
C0000343 | inverse_isa | C0042890 | 25-Hydroxyvitamin D 2 | Vitamins | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body. |
C0000343 | inverse_isa | C1563726 | 25-Hydroxyvitamin D 2 | Bone Density Conservation Agents | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. |
C0000343 | mapped_to | C0251523 | 25-Hydroxyvitamin D 2 | 1,25,28-trihydroxyvitamin D 2 | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | mapped_to | C0525605 | 25-Hydroxyvitamin D 2 | 25-hydroxyvitamin D2-25-glucuronide | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | mapped_to | C0641134 | 25-Hydroxyvitamin D 2 | 24,25,26-trihydroxyvitamin D2 | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | mapped_to | C0641141 | 25-Hydroxyvitamin D 2 | 24,25,28-trihydroxyvitamin D2 | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | mapped_to | C1743914 | 25-Hydroxyvitamin D 2 | 20-hydroxyvitamin D2 | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | mapped_to | C2716990 | 25-Hydroxyvitamin D 2 | 17,20,24-trihydroxyvitamin D2 | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | measures | C1830099 | 25-Hydroxyvitamin D 2 | Ercalcidiol:SCnc:Pt:Ser/Plas:Qn | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | measures | C1954793 | 25-Hydroxyvitamin D 2 | Ercalcidiol:MCnc:Pt:Ser/Plas:Qn | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | measures | C5425165 | 25-Hydroxyvitamin D 2 | Ercalcidiol:MCnc:Pt:BldC:Qn | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | has_component | C1830099 | 25-Hydroxyvitamin D 2 | Ercalcidiol:SCnc:Pt:Ser/Plas:Qn | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | has_component | C1954793 | 25-Hydroxyvitamin D 2 | Ercalcidiol:MCnc:Pt:Ser/Plas:Qn | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | has_component | C2973201 | 25-Hydroxyvitamin D 2 | Calcidiol+ercalcidiol:MCnc:Pt:Ser/Plas:Qn | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | has_component | C3261450 | 25-Hydroxyvitamin D 2 | Calcidiol+ercalcidiol:SCnc:Pt:Ser/Plas:Qn | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | has_component | C4285503 | 25-Hydroxyvitamin D 2 | Calcidiol+ercalcidiol:SCnc:Pt:Ser/Plas:Qn:IA | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | has_component | C4298570 | 25-Hydroxyvitamin D 2 | Calcidiol+ercalcidiol:MCnc:Pt:Ser/Plas:Qn:IA | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | has_component | C4531927 | 25-Hydroxyvitamin D 2 | Calcidiol+ercalcidiol goal:MCnc:Pt:Ser/Plas:Qn | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | has_component | C5381469 | 25-Hydroxyvitamin D 2 | Calcidiol+ercalcidiol/24r-Hydroxycalcidiol+24r-Hydroxyercalcidiol:MRto:Pt:Ser/Plas:Qn | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | has_component | C5381470 | 25-Hydroxyvitamin D 2 | Calcidiol+ercalcidiol/24r-Hydroxycalcidiol+24r-Hydroxyercalcidiol ratio panel:-:Pt:Ser/Plas:- | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | has_component | C5425165 | 25-Hydroxyvitamin D 2 | Ercalcidiol:MCnc:Pt:BldC:Qn | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | has_component | C5425167 | 25-Hydroxyvitamin D 2 | Calcidiol+ercalcidiol:MCnc:Pt:BldC:Qn | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | inverse_isa | C0042866 | 25-Hydroxyvitamin D 2 | vitamin D | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | A vitamin that includes both CHOLECALCIFEROLS and ERGOCALCIFEROLS, which have the common effect of preventing or curing RICKETS in animals. It can also be viewed as a hormone since it can be formed in SKIN by action of ULTRAVIOLET RAYS upon the precursors, 7-dehydrocholesterol and ERGOSTEROL, and acts on VITAMIN D RECEPTORS to regulate CALCIUM in opposition to PARATHYROID HORMONE. |
C0000343 | has_component | C3164018 | 25-Hydroxyvitamin D 2 | Measurement of 25-hydroxyergocalciferol | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | The determination of the amount of 25-hydroxyvitamin D2 present in a sample. |
C0000343 | has_component | C3164648 | 25-Hydroxyvitamin D 2 | Measurement of 25-hydroxyergocalciferol in serum specimen | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000343 | has_component | C4737890 | 25-Hydroxyvitamin D 2 | quantitative assessment of 25-hydroxyvitamins D2 and D3 by liquid chromatography with tandem mass spectrometry | 9,10-Secoergosta-5,7,10(19),22-tetraene-3,25-diol. Biologically active metabolite of vitamin D2 which is more active in curing rickets than its parent. The compound is believed to attach to the same receptor as vitamin D2 and 25-hydroxyvitamin D3. | null |
C0000359 | mapped_to | C0675924 | 3',5'-Cyclic-Nucleotide Phosphodiesterase | regA protein, Dictyostelium | Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP. | null |
C0000359 | mapped_to | C0760980 | 3',5'-Cyclic-Nucleotide Phosphodiesterase | PDE9A protein, human | Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP. | High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (593 aa, ~68 kDa) is encoded by the human PDE9A gene. This protein plays a role in the conversion of cyclic nucleotide monophosphates to non-cyclic monophosphates. |
C0000359 | mapped_to | C1172460 | 3',5'-Cyclic-Nucleotide Phosphodiesterase | PDE8B protein, human | Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP. | High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B (885 aa, ~99 kDa) is encoded by the human PDE8B gene. This protein plays a role in cyclic AMP catabolism. |
C0000359 | mapped_to | C1434796 | 3',5'-Cyclic-Nucleotide Phosphodiesterase | Pde9a protein, rat | Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP. | null |
C0000359 | mapped_to | C1675703 | 3',5'-Cyclic-Nucleotide Phosphodiesterase | Pde9a protein, mouse | Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP. | null |
C0000359 | mapped_to | C1871398 | 3',5'-Cyclic-Nucleotide Phosphodiesterase | Pde8a protein, mouse | Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP. | null |
C0000359 | mapped_to | C1871399 | 3',5'-Cyclic-Nucleotide Phosphodiesterase | PDE8A protein, human | Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP. | null |
C0000359 | mapped_to | C1958693 | 3',5'-Cyclic-Nucleotide Phosphodiesterase | Pde4a protein, rat | Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP. | null |
C0000359 | mapped_to | C2352288 | 3',5'-Cyclic-Nucleotide Phosphodiesterase | PDE8A protein, rat | Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP. | null |
C0000359 | mapped_to | C3657508 | 3',5'-Cyclic-Nucleotide Phosphodiesterase | PDEB1 protein, Trypanosoma brucei | Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP. | null |
C0000359 | inverse_isa | C0020289 | 3',5'-Cyclic-Nucleotide Phosphodiesterase | Hydrolase | Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP. | Any member of the class of enzymes that catalyze the cleavage of the substrate and the addition of water to the resulting molecules, e.g., ESTERASES, glycosidases (GLYCOSIDE HYDROLASES), lipases, NUCLEOTIDASES, peptidases (PEPTIDE HYDROLASES), and phosphatases (PHOSPHORIC MONOESTER HYDROLASES). EC 3. |
C0000359 | inverse_isa | C0033684 | 3',5'-Cyclic-Nucleotide Phosphodiesterase | Proteins | Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP. | Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. |
C0000359 | disposition_of | C4521917 | 3',5'-Cyclic-Nucleotide Phosphodiesterase | Hydrolase (disposition) | Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP. | null |
C0000360 | mapped_to | C1871400 | 3',5'-Cyclic-GMP Phosphodiesterases | PDE11A protein, human | Enzymes that catalyze the hydrolysis of cyclic GMP to yield guanosine-5'-phosphate. | null |
C0000360 | mapped_to | C1871402 | 3',5'-Cyclic-GMP Phosphodiesterases | Pde11a protein, mouse | Enzymes that catalyze the hydrolysis of cyclic GMP to yield guanosine-5'-phosphate. | null |
C0000360 | mapped_to | C2975767 | 3',5'-Cyclic-GMP Phosphodiesterases | YfgF protein, E coli | Enzymes that catalyze the hydrolysis of cyclic GMP to yield guanosine-5'-phosphate. | null |
C0000360 | mapped_to | C3529549 | 3',5'-Cyclic-GMP Phosphodiesterases | PDE6H protein, human | Enzymes that catalyze the hydrolysis of cyclic GMP to yield guanosine-5'-phosphate. | null |
C0000360 | mapped_to | C3852122 | 3',5'-Cyclic-GMP Phosphodiesterases | YahA protein, E coli | Enzymes that catalyze the hydrolysis of cyclic GMP to yield guanosine-5'-phosphate. | null |
C0000360 | mapped_to | C4507391 | 3',5'-Cyclic-GMP Phosphodiesterases | Pde6h protein, mouse | Enzymes that catalyze the hydrolysis of cyclic GMP to yield guanosine-5'-phosphate. | null |
C0000360 | inverse_isa | C0020289 | 3',5'-Cyclic-GMP Phosphodiesterases | Hydrolase | Enzymes that catalyze the hydrolysis of cyclic GMP to yield guanosine-5'-phosphate. | Any member of the class of enzymes that catalyze the cleavage of the substrate and the addition of water to the resulting molecules, e.g., ESTERASES, glycosidases (GLYCOSIDE HYDROLASES), lipases, NUCLEOTIDASES, peptidases (PEPTIDE HYDROLASES), and phosphatases (PHOSPHORIC MONOESTER HYDROLASES). EC 3. |
C0000360 | inverse_isa | C0033684 | 3',5'-Cyclic-GMP Phosphodiesterases | Proteins | Enzymes that catalyze the hydrolysis of cyclic GMP to yield guanosine-5'-phosphate. | Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. |
C0000360 | disposition_of | C4521917 | 3',5'-Cyclic-GMP Phosphodiesterases | Hydrolase (disposition) | Enzymes that catalyze the hydrolysis of cyclic GMP to yield guanosine-5'-phosphate. | null |
C0000370 | inverse_isa | C0007090 | 3,3-Dichlorobenzidine | Carcinogens | A material used in the manufacture of azo dyes that is toxic to skin and carcinogenic in several species. | Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. |
C0000370 | mapped_to | C0046913 | 3,3-Dichlorobenzidine | 3,3-dichloro-N-acetylbenzidine | A material used in the manufacture of azo dyes that is toxic to skin and carcinogenic in several species. | null |
C0000370 | mapped_to | C0215634 | 3,3-Dichlorobenzidine | Pigment Yellow 17 | A material used in the manufacture of azo dyes that is toxic to skin and carcinogenic in several species. | null |
C0000370 | mapped_to | C0615663 | 3,3-Dichlorobenzidine | 3,3'-dichloro-N,N'-diacetylbenzidine | A material used in the manufacture of azo dyes that is toxic to skin and carcinogenic in several species. | null |
C0000370 | mapped_to | C0638856 | 3,3-Dichlorobenzidine | 3,5-dichlorobenzidine | A material used in the manufacture of azo dyes that is toxic to skin and carcinogenic in several species. | null |
C0000370 | mapped_to | C0638858 | 3,3-Dichlorobenzidine | 3,3',5-trichlorobenzidine | A material used in the manufacture of azo dyes that is toxic to skin and carcinogenic in several species. | null |
C0000370 | inverse_isa | C1711315 | 3,3-Dichlorobenzidine | Carcinogenic Aromatic Amine | A material used in the manufacture of azo dyes that is toxic to skin and carcinogenic in several species. | Potentially cancer-causing compound containing amine with an aromatic ring substituted for one or more of its hydrogen atoms, i.e., -NH2, -NH- or nitrogen group(s) attached to an aromatic hydrocarbon, whose structure usually contains one or more benzene rings. This group includes many industrial and tobacco carcinogens. (NCI05) |
C0000370 | subset_includes_concept | C1880653 | 3,3-Dichlorobenzidine | FDA Established Names and Unique Ingredient Identifier Codes Terminology | A material used in the manufacture of azo dyes that is toxic to skin and carcinogenic in several species. | The terminology that includes terms pertaining to FDA/USP Substance Registration System (SRS), which is to support health information technology initiatives by generating unique ingredient identifiers (UNIIs) for substances in drugs, biologics, foods, and devices. |
C0000370 | inverse_isa | C0301233 | 3,3-Dichlorobenzidine | Screening smoke | A material used in the manufacture of azo dyes that is toxic to skin and carcinogenic in several species. | null |
C0000370 | has_component | C1266485 | 3,3-Dichlorobenzidine | Dichlorobenzidine measurement | A material used in the manufacture of azo dyes that is toxic to skin and carcinogenic in several species. | null |
C0000370 | has_measured_component | C1266485 | 3,3-Dichlorobenzidine | Dichlorobenzidine measurement | A material used in the manufacture of azo dyes that is toxic to skin and carcinogenic in several species. | null |
C0000376 | mapped_to | C0046979 | 3,4-Dihydroxyphenylacetic Acid | 3,4-dihydroxyphenylacetaldehyde | A deaminated metabolite of LEVODOPA. | null |
C0000376 | mapped_to | C0608823 | 3,4-Dihydroxyphenylacetic Acid | sulfonyloxydihydroxyphenylacetic acid | A deaminated metabolite of LEVODOPA. | null |
C0000376 | mapped_to | C0629417 | 3,4-Dihydroxyphenylacetic Acid | (4-hydroxy-3-methoxyphenyl)acetaldehyde | A deaminated metabolite of LEVODOPA. | null |
C0000376 | see_from | C0178432 | 3,4-Dihydroxyphenylacetic Acid | 3,4-dihydroxyphenylacetate | A deaminated metabolite of LEVODOPA. | metabolite of DOPA. |
C0000376 | has_member | C0935581 | 3,4-Dihydroxyphenylacetic Acid | Neurotransmitters & Neuroregulators (PsycINFO Subcluster Term) | A deaminated metabolite of LEVODOPA. | null |
C0000376 | inverse_isa | C1291743 | 3,4-Dihydroxyphenylacetic Acid | Catecholamine metabolite | A deaminated metabolite of LEVODOPA. | Molecules created during the catabolism of catecholamine hormones. Increased concentrations of these metabolic products in plasma and urine may indicate the presence of hormone-producing pheochromocytomas or paragangliomas. |
C0000376 | has_component | C4701388 | 3,4-Dihydroxyphenylacetic Acid | 3,4-dihydroxyphenyllactate in urine | A deaminated metabolite of LEVODOPA. | null |
C0000376 | has_component | C4701389 | 3,4-Dihydroxyphenylacetic Acid | urine 3,4-dihydroxyphenyllactate/creatinine ratio | A deaminated metabolite of LEVODOPA. | null |
C0000378 | inverse_isa | C0003405 | droxidopa | Antiparkinson Agents | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. |
C0000378 | mapped_to | C0629676 | droxidopa | 3-(3,4-dihydroxyphenyl)-N-methylserine | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | inverse_isa | C0039052 | droxidopa | Sympathomimetics | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. |
C0000378 | inverse_isa | C1268874 | droxidopa | Amino acid derivative | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | Any derivatives of amino acids that containing amino (-NH2) and carboxyl (-COOH) groups. |
C0000378 | inverse_isa | C1960477 | droxidopa | Hydroxyamino acid | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | inverse_isa | C5434066 | droxidopa | Alpha-adrenergic and beta-adrenergic agonist (disposition) | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_active_ingredient | C3817146 | droxidopa | droxidopa 100 MG Oral Capsule | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_basis_of_strength_substance | C3817146 | droxidopa | droxidopa 100 MG Oral Capsule | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_precise_active_ingredient | C3817146 | droxidopa | droxidopa 100 MG Oral Capsule | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_active_ingredient | C3817392 | droxidopa | droxidopa 300 MG Oral Capsule | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_basis_of_strength_substance | C3817392 | droxidopa | droxidopa 300 MG Oral Capsule | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_precise_active_ingredient | C3817392 | droxidopa | droxidopa 300 MG Oral Capsule | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_active_ingredient | C3817393 | droxidopa | droxidopa 200 MG Oral Capsule | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_basis_of_strength_substance | C3817393 | droxidopa | droxidopa 200 MG Oral Capsule | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_precise_active_ingredient | C3817393 | droxidopa | droxidopa 200 MG Oral Capsule | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_active_ingredient | C3820386 | droxidopa | droxidopa Oral Product | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_active_ingredient | C4752986 | droxidopa | Droxidopa only product | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_active_ingredient | C5191234 | droxidopa | Droxidopa only product in oral dose form | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | disposition_of | C5434066 | droxidopa | Alpha-adrenergic and beta-adrenergic agonist (disposition) | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | inverse_isa | C0003405 | droxidopa | Antiparkinson Agents | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. |
C0000378 | subset_includes_concept | C1880653 | droxidopa | FDA Established Names and Unique Ingredient Identifier Codes Terminology | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | The terminology that includes terms pertaining to FDA/USP Substance Registration System (SRS), which is to support health information technology initiatives by generating unique ingredient identifiers (UNIIs) for substances in drugs, biologics, foods, and devices. |
C0000378 | has_ingredient | C3817146 | droxidopa | droxidopa 100 MG Oral Capsule | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_ingredient | C3817392 | droxidopa | droxidopa 300 MG Oral Capsule | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_ingredient | C3817393 | droxidopa | droxidopa 200 MG Oral Capsule | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_active_ingredient | C3817052 | droxidopa | droxidopa 100 MG Oral Capsule [Northera] | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_active_moiety | C3817052 | droxidopa | droxidopa 100 MG Oral Capsule [Northera] | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_active_ingredient | C3817146 | droxidopa | droxidopa 100 MG Oral Capsule | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_active_moiety | C3817146 | droxidopa | droxidopa 100 MG Oral Capsule | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_active_ingredient | C3817392 | droxidopa | droxidopa 300 MG Oral Capsule | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_active_moiety | C3817392 | droxidopa | droxidopa 300 MG Oral Capsule | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
C0000378 | has_active_ingredient | C3817393 | droxidopa | droxidopa 200 MG Oral Capsule | A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION. | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.